TIAA CREF Investment Management LLC decreased its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 14.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,202 shares of the biotechnology company’s stock after selling 8,839 shares during the period. TIAA CREF Investment Management LLC owned about 0.21% of Mirati Therapeutics worth $266,000 at the end of the most recent quarter.

Separately, Trexquant Investment LP raised its stake in shares of Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares in the last quarter. 60.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded up 0.90% during mid-day trading on Wednesday, reaching $5.60. The company’s stock had a trading volume of 9,970 shares. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $7.22. The company’s market cap is $139.83 million. The company has a 50-day moving average of $4.72 and a 200-day moving average of $4.52.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/30/tiaa-cref-investment-management-llc-sells-8839-shares-of-mirati-therapeutics-inc-mrtx.html.

MRTX has been the subject of a number of recent research reports. Zacks Investment Research raised Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Wednesday, May 3rd. Jefferies Group LLC reissued a “hold” rating and set a $4.50 price objective on shares of Mirati Therapeutics in a report on Monday, June 12th. Finally, ValuEngine raised Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Mirati Therapeutics currently has an average rating of “Hold” and an average price target of $7.75.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.